Advanced Filters
noise

Gayang-si, Korea, Republic of Clinical Trials

A listing of Gayang-si, Korea, Republic of clinical trials actively recruiting patients volunteers.

Found 249 clinical trials
D DoYoun Oh

A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors

This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation study of ABL103 to evaluate the safety, tolerability, MTD (maximum tolerated dose) and/or RP2D (recommended phase 2 dose), pharmacokinetics, immunogenicity, preliminary antitumor activity of ABL103 in subjects with any progressive locally advanced(unresectable) or metastatic solid tumor who are relapsed …

18 years of age All Phase 1

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.

18 years of age Female Phase 2
M Moonki Choi, M.D., Ph.D.

Study of DNP002 in Patients With Solid Tumors

This is an open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of the anti-Carcinoembryonic-antigen-related-cell-adhesion-molecule-6 (CEACAM6) antibody DNP002 in patients with advanced solid tumors.

19 years of age All Phase 1
H Hyun Woong Cho, Ph.D

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma. 198 subjects will be enrolled in this study and will be assigned to three groups in a 1:1:1 ratio. Group A: Dostarlimab monotherapy First 3 cycles: Dostalimab 500mg every …

18 years of age Female Phase 2
H Ho Kyung Seo

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

The aim of this study is to evaluate the effectiveness and safety of mitomycin-c and gemcitabine sequential instillation in BCG unresponsive high risk non-muscle invasive bladder cancer patients.

20 years of age All Phase 2
H Hyery KIM, MD, PhD

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.

1 - 9 years of age All Phase 2
S Site Contact

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

This study is open-label, multi-center, prospective study, which targets childhood patients with relapsed acute lymphostatic leukemia including bone marrow recurrence. Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for relapsed acute lymphoblastic leukemia in children and adolescents.

1 - 22 years of age All Phase 2
H Heeyoung Ju, MD, PhD

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

Clinical and genetic factors consistent with High risk : Induction → Consolidation BM MRD < 0.01% : IM #1 → DI #1 → IM #2 → Maintenance BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance BM MRD ≥ 0.01% after …

1 - 19 years of age All Phase 2
S Sang Myung Woo, PI

Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

[Study objectives] To evaluate the efficacy and safety of the combined treatment of radiotherapy and endoscopic intraductal radiofrequency ablation in patients with locoregional extrahepatic cholangiocarcinoma.

20 years of age All Phase N/A
J Jung-Yun Lee

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

phase 2 clinical trial to confirm the pathological complete response rate of PD-1 blocker use in patients with Mismatch Repair Deficiency(MMRd) endometrial cancer that can be completely resected surgically.

20 years of age Female Phase 2

Simplify language using AI